Recursion Pharmaceuticals (RXRX) Competitors $5.26 +0.05 (+0.96%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$5.18 -0.08 (-1.43%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXRX vs. BPMC, BBIO, VRNA, ROIV, ELAN, RVMD, LEGN, GRFS, TGTX, and LNTHShould you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Recursion Pharmaceuticals vs. Its Competitors Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Elanco Animal Health Revolution Medicines Legend Biotech Grifols TG Therapeutics Lantheus Recursion Pharmaceuticals (NASDAQ:RXRX) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment. Do analysts prefer RXRX or BPMC? Recursion Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 33.08%. Blueprint Medicines has a consensus target price of $128.06, indicating a potential downside of 0.16%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.27 Does the media prefer RXRX or BPMC? In the previous week, Recursion Pharmaceuticals had 4 more articles in the media than Blueprint Medicines. MarketBeat recorded 9 mentions for Recursion Pharmaceuticals and 5 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.81 beat Recursion Pharmaceuticals' score of 0.54 indicating that Blueprint Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in RXRX or BPMC? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 4.2% of Blueprint Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has better valuation & earnings, RXRX or BPMC? Blueprint Medicines has higher revenue and earnings than Recursion Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$58.84M36.34-$463.66M-$1.77-2.97Blueprint Medicines$508.82M16.28-$67.09M-$2.47-51.93 Which has more risk and volatility, RXRX or BPMC? Recursion Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Is RXRX or BPMC more profitable? Blueprint Medicines has a net margin of -27.70% compared to Recursion Pharmaceuticals' net margin of -961.32%. Blueprint Medicines' return on equity of -64.60% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-961.32% -74.70% -54.02% Blueprint Medicines -27.70%-64.60%-17.22% SummaryRecursion Pharmaceuticals beats Blueprint Medicines on 9 of the 17 factors compared between the two stocks. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXRX vs. The Competition Export to ExcelMetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.14B$2.43B$5.53B$9.02BDividend YieldN/A1.78%5.22%3.99%P/E Ratio-2.979.1527.7920.25Price / Sales36.34680.43426.06119.26Price / CashN/A21.7726.2128.59Price / Book2.024.558.045.65Net Income-$463.66M$31.26M$3.18B$249.15M7 Day Performance3.95%2.98%2.89%2.91%1 Month Performance-4.19%3.46%1.67%4.11%1 Year Performance-28.14%0.77%34.53%20.98% Recursion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXRXRecursion Pharmaceuticals1.7586 of 5 stars$5.26+1.0%$7.00+33.1%-28.1%$2.14B$58.84M-2.97400BPMCBlueprint Medicines1.5405 of 5 stars$128.14+0.0%$128.06-0.1%+14.8%$8.28B$562.12M-51.88640BBIOBridgeBio Pharma4.6879 of 5 stars$43.03-4.1%$58.85+36.8%+69.7%$8.17B$221.90M-12.19400VRNAVerona Pharma PLC American Depositary Share2.7874 of 5 stars$94.57+0.8%$101.10+6.9%+466.0%$8.05B$42.28M-47.2930Positive NewsROIVRoivant Sciences1.5219 of 5 stars$11.26-1.1%$17.50+55.4%+1.8%$7.65B$29.05M-45.04860ELANElanco Animal Health2.3849 of 5 stars$14.25-0.3%$15.17+6.4%+3.0%$7.08B$4.44B19.269,000Analyst UpgradeRVMDRevolution Medicines4.5774 of 5 stars$36.88-0.1%$67.58+83.3%-1.4%$6.87B$11.58M-9.22250LEGNLegend Biotech3.1003 of 5 stars$35.80+3.4%$76.20+112.8%-23.7%$6.58B$627.24M-60.682,609Positive NewsGRFSGrifols4.1158 of 5 stars$8.93+0.8%$10.30+15.3%+28.9%$6.14B$7.81B7.6323,822News CoverageAnalyst UpgradeTGTXTG Therapeutics3.2919 of 5 stars$35.98-2.0%$40.80+13.4%+95.7%$5.71B$329M149.92290LNTHLantheus4.4551 of 5 stars$82.20+0.9%$130.50+58.8%+0.4%$5.69B$1.53B23.35700Positive News Related Companies and Tools Related Companies Blueprint Medicines Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Elanco Animal Health Competitors Revolution Medicines Competitors Legend Biotech Competitors Grifols Competitors TG Therapeutics Competitors Lantheus Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXRX) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.